1American Heart Association. 2002 heart and stroke statistical update.Dallas: The Association; 2001.
2Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA, 2000, 284:2901 - 2906.
3Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional out-come, survival,and recurrence. Stroke, 2000, 31:1062 -1068.
4Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.Circulation, 2002, 105: 1135 - 1143.
5Libby P, Simon DI. Inflammation and thrombosis: the clot thickens.Circulation, 2001, 103:1718 - 1720.
6Saito M, Ishimitsu T, Minami J, et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors.Atherosclerosis, 2003, 167:73 -79.
7Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke, 2001, 32:2575 -2579.
8Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ, 2002,324:71 - 86.
9Diener HC, Darius H, Bertrand-Hardy JM, et al. European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract, 2001, 55:162 - 163.
10A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee.Lancet, 1996, 348:1329 - 1339.
